NASDAQ:PDEX opened at $14.89 on Friday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 2.81 and a current ratio of 4.37. The company has a market cap of $53.89 million, a PE ratio of 17.11 and a beta of 1.12. Pro-Dex has a 52-week low of $12.40 and a 52-week high of $35.93. The stock has a 50-day simple moving average of $15.56 and a 200 day simple moving average of $20.32.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Morgan Stanley lifted its position in shares of Pro-Dex by 149.7% in the second quarter. Morgan Stanley now owns 2,622 shares of the medical instruments supplier’s stock valued at $80,000 after buying an additional 1,572 shares during the last quarter. Wells Fargo & Company MN increased its stake in shares of Pro-Dex by 11.2% in the 2nd quarter. Wells Fargo & Company MN now owns 3,283 shares of the medical instruments supplier’s stock valued at $101,000 after purchasing an additional 331 shares during the last quarter. JPMorgan Chase & Co. bought a new stake in Pro-Dex during the 4th quarter worth $313,000. LSV Asset Management increased its holdings in Pro-Dex by 13.9% in the 1st quarter. LSV Asset Management now owns 35,581 shares of the medical instruments supplier’s stock worth $588,000 after purchasing an additional 4,346 shares in the last quarter. Finally, BlackRock Inc. increased its holdings in Pro-Dex by 10.7% in the 3rd quarter. BlackRock Inc. now owns 49,114 shares of the medical instruments supplier’s stock worth $1,261,000 after purchasing an additional 4,752 shares in the last quarter. 16.73% of the stock is owned by institutional investors.
Pro-Dex, Inc designs, develops, and manufactures powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.
- Get a free copy of the StockNews.com research report on Pro-Dex (PDEX)
- Carvana Insiders Buy Shares But Maybe You Shouldn’t
- Dutch Bros Gets Scalded By Inflation
- The S&P 500 Could Fall Another 28%
- Corning Stock is a Technology Value Play
- Anheuser-Busch InBev May Need One More Quarter to Confirm a Buy Signal
Receive News & Ratings for Pro-Dex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pro-Dex and related companies with MarketBeat.com's FREE daily email newsletter.